Can a PET scan predict immunotherapy success in melanoma?
NCT ID NCT03356470
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This small pilot study tested whether special PET scans (FLT PET/CT) could detect early signs that immunotherapy is working in people with advanced melanoma. Five participants received standard immunotherapy drugs (pembrolizumab or nivolumab) and had scans, blood tests, and tumor biopsies before and during treatment. The goal was to find a biomarker that predicts response, not to test the drugs themselves.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FLT PET/CT imaging
What this could lead to
If successful, this could help doctors predict which melanoma patients will benefit from immunotherapy, avoiding unnecessary treatments.
What could go wrong
This is a very small pilot study with only 5 participants, so results may not apply to all patients. It is exploratory and not designed to prove treatment effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States